JCOGの基本情報 > 研究実績 > 旧消化器がん内科グループ

JCOGの基本情報旧消化器がん内科グループ

更新日：2011年8月1日


消化器がん内科グループは、2011年4月をもって、胃がんグループ、消化器内視鏡グループ、頭頸部がんグループへと発展的改組となりました。


  1. 論文
    1. 委員会承認の治療研究
      JCOG8501
      M Kurihara, T Izumi, S Yoshida, et al.: A Cooperative Randomized Study on Tegafur plus Mitomycin C versus Combined Tegafur and Uracil plus Mitomycin C in the Treatment of Advanced Gastric Cancer. Jpn J Cancer Res. 82: 613-620, 1991.
      JCOG8804
      W Koizumi, M Kurihara, T Sasaki, et al.: A Phase II Study of Combination Therapy with 5’-Deoxy-5-Fluorouridine and Cisplatin in the Treatment of Advanced Gastric Cancer with Primary Foci. Cancer. 72(3): 658-662, 1993.
      JCOG8903
      島田安博、吉田茂昭：可能性の開けた胃癌の化学療法（EAP療法）. 代謝. Vol. 28増刊号「癌’91」：235-242, 中山書店, 1991.
      JCOG9001
      A Ohtsu, Y Shimada, S Yoshida, et al.: Phase II Study of Protracted Infusional 5-fluorouracil Combined with Cisplatinum for Advanced Gastric Cancer: Report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer. 30A (14): 2091-2093, 1994.
      JCOG9205
      A Ohtsu, Y Shimada, K Shirao, et al.: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 21(1): 54-59, 2003.
      JCOG9207
      T Hamaguchi, K Shirao, N Yamamichi, et al.: A Phase II Study of Sequential Methotrexate and 5-fluorouracil Chemotherapy in Previously Treated Gastric Cancer: A Report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 Trial. Jpn J Clin Oncol. 38(6): 432-437, 2008
      JCOG9410
      N Ikeda, Y Shimada, A Ohtsu, et al.: A phase II study of doxifluridine in elderly patients with advanced gastric cancer: Japan Clinical Oncology Group (JCOG9410). Jpn J Clin Oncol. 32(3): 90-94, 2002.
      JCOG9603
      T Yamao, Y Shimada, K Shirao, et al.: Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the gastrointestinal oncology study group of the japan clinical oncology group, JCOG 9603 Trial. Jpn J Clin oncol 34: 316-322, 2004.
      JCOG9703
      A Ohtsu, N Boku, T Yoshioka, et al.: A phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703). Jpn J Clin Oncol. 33(1): 28-32, 2003.
      JCOG9908
      S Ishikura, A Ohtsu, K Shirao, et al.: A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with T4 esophageal cancer: Japan Clinical Oncology Group trial (JCOG9908). Esophagus 2: 133-137, 2005
      JCOG9911-DI
      Y Yamada, K Shirao, A Ohtsu, et al: Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. Cancer Chemother Pharmacol. 52: 125-130, 2003.
      JCOG9912：
      N Boku, S Yamamoto, H Fukuda, et al.: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: randomised phase 3 study. Lancet Oncology. 10(11): 1063-1069, 2009
      JCOG0506
      H Ishii, J Furuse, N Boku, et al.: Phase II Study of Gemcitabine Chemotherapy Alone for Locally Advanced Pancreatic Carcinoma: JCOG0506. Jpn J Clin Oncol. 40(6):573-579, 2010.
      JCOG0508
      Y Kurokawa, M Muto, K Minashi, et al.: A Phase II Trial of Combined Treatment of Endoscopic Mucosal Resection and Chemoradiotherapy for Clinical Stage I Esophageal Carcinoma: Japan Clinical Oncology Group Study JCOG0508. Jpn J Clin Oncol. 39(10): 686-689, 2009.
      JCOG0607
      Y Kurokawa, N Hasuike, H Ono, et al.: A Phase II Trial of Endoscopic Submucosal Dissection for Mucosal Gastric Cancer: Japan Clinical Oncology Group Study JCOG0607. Jpn J Clin Oncol. 39(7): 464-466, 2009
      JCOG0706
      K Nakamura, M Tahara, N Kiyota, et al.: Phase II Trial of Concurrent Chemoradiotherapy with S-1 Plus Cisplatin in Patients with Unresectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Japan Clinical Oncology Group Study (JCOG0706). Jpn J Clin Oncol. 39(7): 460-463, 2009.
      JCOG0109-DI
      T Hamaguchi, K Shirao, A Ohtsu, et al.; Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group: A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial). Gastric Cancer. 2011. [Epub ahead of print]
      JCOG9906
      K Kato, K Muro, K Minashi, et al.; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (JCOG): Phase II Study of Chemoradiotherapy with 5-Fluorouracil and Cisplatin for Stage II-III Esophageal Squamous Cell Carcinoma: JCOG Trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2010. [Epub ahead of print]
      JCOG0506
      H Ishii, J Furuse, N Boku, et al.; JCOG Gastrointestinal Oncology Study Group. Phase II Study of Gemcitabine Chemotherapy Alone for Locally Advanced Pancreatic Carcinoma: JCOG0506. Jpn J Clin Oncol. 40(6): 573-579, 2010.
    2. グループ代表者管理の治療研究
      • なし
    3. 附随研究等
      JCOG8501, 8804, 8903, 9001
      M Ohkuwa, A Ohtsu, N Boku, et al.: Long-term results for patiants with unresectable gastric cancer who received chemotherapy in the Japan Clinical Oncology Group (JCOG) trials. Gastric Cancer. 3: 145-150, 2000.
      M Yoshida, A Ohtsu, N Boku, et al.: Long-term Survival and Prognostic Factors in Patients with Metastatic Gastric Cancers Treated with Chemotherapy in the Japan Clinical Oncology Group (JCOG) Study. Jpn J Clin Oncol 34(11):1-6, 2004.
      JCOG9205
      N Boku, A Ohtsu, S,Yoshida et al.: Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. Jpn. J. Clin. Oncol. 37: 275-281, 2007.
    4. 総説・解説
      Y Shimada: Clinical trials for advanced gastrointestinal cancers in Japan. Japan Clinical Oncology Group Gastrointestinal Oncology Study Group. Cancer Chemother Pharmacol. 42 Suppl:S80-4, 1998.
      A Ohtsu, S Yoshida: Chemotherapy and chemoradiotherapy for esophageal cancer. Crit Rev Oncol Hematol. 28(3):173-180, 1998.
      A Ohtsu: The latest advances in chemotherapy for gastrointestinal cancers. Int J Clin Oncol. 8(4):234-238, 2003.
      A Ohtsu: Chemoradiotherapy for esophageal cancer: current status and perspectives. Int J Clin Oncol. 9(6):444-450, 2004.
      N Boku: Chemotherapy for metastatic gastric cancer results from clinical trials in Asia, Cancer Reviews: Asian Pacific 2(1): 61-67, 2004.
      A Ohtsu: Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer. 2005;8(2):95-102.
      A Ohtsu, S Yoshida, N Saijo: Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 24(14):2188-2196, 2006.
      A Ohtsu: Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol. 43(4):256-264, 2008.
      N Boku: Chemotherapy for metastatic disease: review from JCOG trials. Int J Clin Oncol 13:196-200, 2008.
      N Boku: Chemotherapy for metastatic gastric cancer in Japan. Int J Clin Oncol. 13(6): 483-487, 2008.
      N Boku: JCOG trials of systemic chemotherapy for unresectable or recurrent gastric cancer. Gastric Cancer. 12(Supple 1): 43-49, 2008.
      N Boku: Perspectives for personalization in chemotherapy of advanced gastric cancer. Discov Med. 9(45): 84-89, 2010.
  2. 主な学会発表
    1. 委員会承認の治療研究
      JCOG9205
      Y Shimada, K Shirao, A Ohtsu, et al.: Phase III study of UFT+MMC vs 5-FU+CDDP vs 5-FU alone in patients with advanced gastric cancer. Annual Meeting of the American Society of Clinical Oncology. 1999. Proc Am Soc Clin Oncol. 18: 1043, 1999.
      JCOG9603
      K Muro, K Shirao, Y Shimada, et al: A phase II study of sequential Methotrexate and 5-Fuluorouracil for advanced gastric cancer with malignant ascites: JCOG9603. Annual Meeting of the American Society of Clinical Oncology. 2001.
      JCOG9703
      T Yoshioka, A Ohtsu, I Hyodo, et al.: Phase II study of a combination of Irinotecan and 5-day infusional 5-fluorouracil in patients with metastatic colorectal cancer: A Japan Clinical Oncology Group (JCOG) 9703. Annual Meeting of the American Society of Clinical Oncology. 2000. Proc Am Soc Clin Oncol. 19: 1142, 2000.
      JCOG9906
      K Minashi, K Muro, K Kato, et al.: A phase II study of chemoradiotherapy in patients (pts) with stage II, III esophageal squamous cell carcinoma (ESCC): JCOG trial (JCOG 9906). Gastrointestinal Cancers Symposium, abstract# 114, 2008
      JCOG9908-DI
      S Ishikura, A Ohtsu, K Shirao, et al.: A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with T4 esophageal cancer: Japan Clinical Oncology Group study (JCOG9908-DI), Proc Am Soc Clin Oncol. 22: 276, 2003.
      JCOG9911-DI
      Y Yamada, K Shirao, I Hyodo, et al: Phase II study of irinotecan plus mitomycin C in patients with fluoropyrimidine-resistant advanced colorectal cancer. Ann Oncol. 13 (S5) : 86, 2002.
      JCOG9912
      N. Boku, S. Yamamoto, K. Shirao, et al: Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912), ASCO 2007 LBA4513
      JCOG0106
      K Shirao, N Boku, Y Yamada, et al.: Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106).　Annual meeting of ASCO 2009. J Clin Oncol. 27:15s, 2009 (suppl; abstr 4545)
      JCOG0407
      H Takiuchi, H Fukuda, N Boku, et al.: Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407). Annual meeting of ASCO 2010. J Clin Oncol. 28:7s, 2010 (suppl; abstr 4052)
      JCOG0506
      H Ishii, J Furuse, N Boku, et al.: Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506. Annual meeting of ASCO 2009. J Clin Oncol. 27, 2009 (suppl; abstr e15578)
      JCOG0508
      T Tsuchida, M Muto, K Minashi, et al.: A phase II trial of combined treatment of endoscopic mucosal resection (EMR) and chemoradiotherapy (CRT) for clinical stage I esophageal squamous cell carcinoma (ESCC): Japan Clinical Oncology Group study JCOG0508. Annual meeting of ASCO 2010. J Clin Oncol. 28:7s, 2010 (suppl; abstr TPS204)
    2. グループ代表者管理の治療研究
      H Takiuchi, H Yasui, T Nishina, et al.: Multicenter feasibility study of 5-FU, leucovorin, plus paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake ASCO-GI, J Clin Oncol 29: (suppl 4; abstr 119) 2011.
      T Tsushima, N Boku, Y Honma, et al. Retrospective analysis of first-line chemotherapy in 132 patients with advanced small-bowel adenocarcinoma. ASCO-GI, J Clin Oncol 29: (suppl 4; abstr 260) 2011.
    3. 附随研究等
      JCOG8501, 8804, 8903, 9001
      M Ohkuwa, Y Miyata, A Ohtsu, et al.: Long-term results of patients with unresectable gastric carcinoma treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) trials. 3rd International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies. Sep 1998.
      JCOG8501, 8804, 8903, 9001, 9205
      M Yoshida, A Ohtsu, N Boku, et al.: Long-term survival of patients with unresectable gastric cancer treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Annual Meeting of the American Society of Clinical Oncology. 2001. Proc Am Soc Clin Oncol. 20: abstr 652, 2001.
      JCOG9205
      N Boku, A Ohtsu, K Shirao, et al.: Siginificance of biological markers in patients with advanced gastric cancer terated with 5FU + CDDP and 5-FU continuous infusion. Annual Meeting of the American Society of Clinical Oncology. 2000. Proc Am Soc Clin Oncol. 19: abstr 1022, 2000.
      JCOG9912
      Y Kurokawa, T Yamaguchi, K. Yoshimura, et al.: Evaluation of heterogeneities in treatment effects and baseline risks among hospitals: additional result of JCOG9912 phase III trial for advanced gastric cancer. Annual meeting of ASCO 2008. J Clin Oncol. 26: 2008 (suppl; abstr 6638).
      N Fuse, H Fukuda, Y Yamada, et al.: Updated results of randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912). Annual meeting of ASCO 2009. J Clin Oncol. 27:15s, 2009 (suppl; abstr 4514).
      Y Yamada, S Yamamoto, A Ohtsu, et al.: Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912. Annual meeting of ASCO 2009. J Clin Oncol. 27:15s, 2009 (suppl; abstr 4535).
      D Takahari, A Takashima, J Mizusawa,et al.: Prognostic factors in Japanese patients with advanced gastric cancer using the data from JCOG9912 study. Annual Meeting of ASCO, J Clin Oncol 29: 2011(suppl; abstr 4059).
      Y Yamada, J Mizusawa, A Takashima, et al.: Molecular prognostic markers in advanced gastric cancer: Correlative study in the Japan Clinical Oncology Group trial JCOG9912. Annual Meeting of ASCO, J Clin Oncol 29: 2011 (suppl; abstr 4021).
      JCOG9205, 9912
      A Takashima, N Boku, K Kato, et al.: Survival prolongation after treatment failure in patients with advanced gastric cancer (AGC): Results from combined analysis of JCOG9205 and JCOG9912. Annual meeting of ASCO 2010. J Clin Oncol. 28:7s, 2010 (suppl; abstr 4061)
    4. 総説・解説
      • なし
トップへ戻る